PARAMEDIC2试验与德国复苏登记处结局差异:随机对照试验与登记数据的二次分析
本研究利用PARAMEDIC2试验已发表的汇总数据与德国复苏登记处(GRR)中26 019例因院外心脏骤停(OHCA)接受肾上腺素治疗的患者数据,建立基于逻辑回归的建模框架进行比较。基线模型纳入年龄、性别、初始心律、心脏骤停病因、目击情况、旁观者CPR及呼叫至到达间隔等变量。结果显示,具有PARAMEDIC2基线特征的患者在德国体系下出院生存率为7.7%、神经功能良好生存率为5.0%,而试验肾上腺素组分别为3.2%和2.2%。加入治疗相关变量后,上述率分别降至5.6%和3.4%。该框架有助于解读PARAMEDIC2试验结果及其对其他急救系统的可移植性。
要点
- 在德国急救与医疗体系下,具有PARAMEDIC2试验基线特征的患者出院生存率预计为7.7%,神经功能良好生存率为5.0%。
- PARAMEDIC2试验肾上腺素组的出院生存率为3.2%,神经功能良好生存率为2.2%,低于上述德国体系下的预测值。
- 在模型中加入治疗相关变量(气道管理类型、血管通路类型、肾上腺素给药时间)后,出院生存率从7.7%降至5.6%,神经功能良好生存率从5.0%降至3.4%。
- GRR中因OHCA接受肾上腺素治疗的患者共26 019例,用于与PARAMEDIC2试验数据比较。
- 作者认为,其他急救与医疗体系可能实现比PARAMEDIC2试验报告更高的生存率和神经功能良好生存率。
适用人群与场景
- PARAMEDIC2试验纳入的院外心脏骤停(OHCA)患者。
- 德国复苏登记处(GRR)中因OHCA接受肾上腺素治疗的患者,共26 019例。
研究设计与关键结果
- 研究设计:基于PARAMEDIC2试验已发表的汇总数据与德国复苏登记处(GRR)数据的二次分析,采用基于逻辑回归的建模框架进行比较。
- GRR队列共纳入26 019例因OHCA接受肾上腺素治疗的患者。
- 基线模型纳入年龄、性别、初始心律、心脏骤停病因、目击情况、旁观者CPR及呼叫至到达间隔等变量。
- 具有PARAMEDIC2试验基线特征的患者在德国急救与医疗体系下,出院生存率为7.7%,神经功能良好生存率为5.0%。
- PARAMEDIC2试验肾上腺素组的出院生存率为3.2%,神经功能良好生存率为2.2%。
- 在基线模型中加入治疗相关变量(气道管理类型、血管通路类型、肾上腺素给药时间)后,出院生存率从7.7%降至5.6%,神经功能良好生存率从5.0%降至3.4%。
证据类型、等级与局限
- 证据类型:随机对照试验(PARAMEDIC2)与登记数据(GRR)比较的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该框架有助于对PARAMEDIC2试验进行医学解读,并评估该试验结果对其他急救系统的可移植性。
- 作者认为,其他急救与医疗体系可能实现比PARAMEDIC2试验报告更高的生存率和神经功能良好生存率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND IMPORTANCE: There has been much discussion of the results of the PARAMEDIC2 trial, as resuscitation outcome rates are considerably lower in this trial than in country-level registries on out-of-hospital cardiac arrest (OHCA). Here, we developed a statistical framework to investigate this gap and to examine possible sources for observed discrepancies in outcome rates.
DESIGN: Summary data from the PARAMEDIC2 trial were used as available in the publication of this study. We developed a modelling framework based on logistic regression to compare data from this randomized controlled trial and registry data from the German Resuscitation Registry (GRR), where we considered 26 019 patients treated with epinephrine for OHCA in the GRR. To account and adjust for differences in patient characteristics and baseline variables predictive for outcomes after OHCA between the GRR cohort and the PARAMEDIC2 study sample, we included all available variables determined at the arrival of EMS personnel in the modelling framework: age, sex, initial cardiac rhythm, cause of cardiac arrest, witness of cardiac arrest, CPR performed by a bystander, and the interval between emergency call and arrival of the ambulance at the scene (baseline model). In order to find possible explanations for the discrepancies in outcome between PARAMEDIC2 and GRR, in a second (baseline plus treatment) model, we additionally included all available variables related to the interventions of the EMS personnel (type of airway management, type of vascular access, and time to administration of epinephrine).
MAIN RESULTS: A patient cohort with baseline variables as in the PARAMEDIC2 trial would have survived to hospital discharge in 7.7% and survived with favourable neurological outcome in 5.0% in an EMS and health care system as in Germany, compared with 3.2 and 2.2%, respectively, in the Epinephrine group of the trial. Adding treatment-related variables to our logistic regression model, the rate of survival to discharge would decrease from 7.7 (for baseline variables only) to 5.6% and the rate of survival with favourable neurological outcome from 5.0 to 3.4%.
CONCLUSION: Our framework helps in the medical interpretation of the PARAMEDIC2 trial and the transferability of the trial's results for other EMS systems. Significantly higher rates of survival and favourable neurological outcome than reported in this trial could be possible in other EMS and health care systems.
参考来源
- Knapp J, Huber M, Gräsner JT, et al. Outcome differences between PARAMEDIC2 and the German Resuscitation Registry: a secondary analysis of a randomized controlled trial compared with registry data. Eur J Emerg Med. 2022. PMID: 35791269. doi:10.1097/MEJ.0000000000000958
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。